The role of microRNAs in the pathogenesis and progression of liver diseases

Sylwia Szeląg, Mateusz Kurzawski

Abstract


MicroRNAs are short non-coding RNAs that regulate the expression of genes at the post-transcriptional level. They play a key role in a number of biological processes, including cell differentiation, immune response, apoptosis and metabolism regulation. They are also directly or indirectly involved in the development and progression of numerous diseases. In liver diseases there are many microRNAs, including miR-122, whose expression depends on the disease aetiology. Therefore, analysis of microRNA proϐile may have a diagnostic and prognostic value, and in the future may be useful in planning liver disease therapy.

Keywords


miRNA; liver failure; regulation of gene expression.

Full Text:

PDF (Język Polski)

References


Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: Function, detection, and bioanalysis. Chem Rev 2013;113(8):6207-33.

Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2011;80(2):193-208.

Hepatitis B. Fact sheet 204. World Healt Organization; 2016. http://www. who.int/mediacentre/factsheets/fs204/en/ (13.04.2016).

Sarkar N, Chakravarty R. Hepatitis B. Virus infection, microRNAs and liver disease. Int J Mol Sci 2015;16(8):17746-62.

Elmore LW, Hancock AR, Chang SF, Wang XW, Chang S, Callahan CP, et al.Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci U S A 1997;94(26):14707-12.

Feng Z, Zhang C, Wu R, Hu W. Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 2011;3(1):44-50. doi: 10.1093/jmcb/mjq040.

Lim KH, Choi HS, Park YK, Park ES, Shin GC, Kim DH, et al. HBx-induced NF-κB signaling in liver cells is potentially mediated by the ternary complex of HBx with p22-FLIP and NEMO. PLoS One 2013;8(3):e57331.

Li JF, Dai XP, Zhang W, Sun SH, Zeng Y, Zhao GY, et al. Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H. MBio 2015;6(2):e02459-14.

Scisciani C, Vossio S, Guerrieri F, Schinzari V, De Iaco R, D’Onorio de Meo P, et al. Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol 2012;56(4):855-61.

Wu G, Yu F, Xiao Z, Xu K, Xu J, Tang W, et al. Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer 2011;105(1):146-53.

Kong G, Zhang J, Zhang S, Shan C, Ye L, Zhang X. Upregulated microRNA-29a by hepatitis B virus X protein enhances hepatoma cell migration by targeting PTEN in cell culture model. PLoS One 2011;6(5):e19518.

Ren M, Qin D, Li K, Qu J, Wang L, Wang Z, et al. Correlation between hepatitis B virus protein and microRNA processor Drosha in cells expressing HBV. Antiviral Res 2012;94(3)225-31.

Bandopadhyay M, Banerjee A, Sarkar N, Panigrahi R, Datta S, Pal A, et al. Tumor suppressor micro RNA miR-145 and onco micro RNAs miR-21 and miR-222 expressions are differentially modulated by hepatitis B virus X protein in malignant hepatocytes. BMC Cancer 2014;14:721.

Wang Y, Lu Y, Toh ST, Sung WK, Tan P, Chow P, et al. Lethal-7 is downregulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol 2010;53(1):57-66. doi: 10.1016/j.jhep.2009.12.043.

Wei X, Xiang T, Ren G, Tan C, Liu R, Xu X, et al. MiR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal 2013;25(2):439-46. doi: 10.1016/j.cellsig.2012.10.013.

Wei X, Tan C, Tang C, Ren G, Xiang T, Qiu Z, et al. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal 2013;25(5):1037-43.

Zhang T, Zhang J, Cui M, Liu F, You X, Du Y, et al. Hepatitis B virus X protein inhibits tumor suppressor miR-205 through inducing hypermethylation of miR-205 promoter to enhance carcinogenesis. Neoplasia 2013;15(11):1282-91.

Zhang X, Zhang E, Ma Z, Pei R, Jiang M, Schlaak JF, et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology 2011;53(5):1476-85.

Dai X, Zhang W, Zhang H, Sun S, Yu H, Guo Y, et al. Modulation of HBV replication by microRNA-15b through targeting hepatocyte nuclear factor 1α. Nucleic Acids Res 2014;42(10):6578-90.

Guo H, Liu H, Mitchelson K, Rao H, Luo M, Xie L, et al. MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. Hepatology 2011;54(3):808-19.

Jin J, Tang S, Xia L, Du R, Xie H, Song J, et al. MicroRNA-501 promotes HBV replication by targeting HBXIP. Biochem Biophys Res Commun 2013;430(4):1228-33.

Zhang GL, Li YX, Zheng SQ, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res 2010;88(2):169-75.

Potenza N, Papa U, Mosca N, Zerbini F, Nobile V, Russo A. Human microRNA hsa-miR-125a-5p interferes with expression of hepatitis B virus surface antigen. Nucleic Acids Res 2011;39(12):5157-63.

Huang JY, Chou SF, Lee JW, Chen HL, Chen CM, Tao MH, et al. MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and PPARγ. RNA 2015;21(3):385-400.

Hu W, Wang X, Ding X, Li Y, Zhang X, Xie P, et al. MicroRNA-141 represses HBV replication by targeting PPARA. PLoS One 2012;7(3):e34165.

Wu FL, Jin WB, Li JH, Guo AG. Targets for human encoded microRNAs in HBV genes. Virus Genes 2011;42(2):157-61.

Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity. Hepatology 2012;55(3):730-41.

Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, et al. MiR-122-induced downregulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun 2010;398(4):771-7.

Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009;49(5):1571-82.

Hepatitis C. Fact sheet 164. World Healt Organization; 2016. http://www. who.int/mediacentre/factsheets/fs164/en/ (13.04.2016).

Conrad KD, Niepmann M. The role of microRNAs in hepatitis C virus RNA replication. Arch Virol 2014;159(5):849-62.

Li Y, Masaki T, Yamane D, McGivern DR, Lemon SM. Competing and noncompeting activities of miR-122 and the 5’ exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 2013;110(5):1881-6. doi: 10.1073/pnas.1213515110.

Machlin ES, Sarnow P, Sagan SM. Masking the 5’ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011;108(8):3193-8.

Motavaf M, Safari S, Alavian SM. Targeting microRNA-122: walking on cutting edge of hepatitis C virus infection therapy. Acta Virol 2014;58(4): 301-8.

Cheng JC, Yeh YJ, Tseng CP, Hsu SD, Chang YL, Sakamoto N, et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012;69(15):2621-33.

Murakami Y, Aly HH, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009;50(3):453-60.

Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007;449(7164):919-22.

Mukherjee A, Shrivastava S, Bhanja Chowdhury J, Ray R, Ray RB. Transcriptional suppression of miR-181c by hepatitis C virus enhances homeobox A1 expression. J Virol 2014;88(14):7929-40.

Gramenzi A, Caputo F, Biselli M, Kuria F, Loggi E, Andreone P, et al. Review article: alcoholic liver disease: pathophysiological aspects and risk factors. Aliment Pharmacol Ther 2006;24(8):1151-61.

Bala S, Marcos M, Kodys K, Csak T, Catalano D, Mandrekar P, et al. Upregulation of microRNA-155 in macrophages contributes to increased tumor necrosis factor {alpha} (TNF{alpha}) production via increased mRNA half-life in alcoholic liver disease. J Biol Chem 2011;286(2):1436-44.

Tang Y, Banan A, Forsyth CB, Fields JZ, Lau CK, Zhang LJ, et al. Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res 2008;32(2):355-64.

Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem 2012;287(13):9817-26.

Dolganiuc A, Petrasek J, Kodys K, Catalano D, Mandrekar P, Velayudham A, et al. MicroRNA expression profile in Lieber-DeCarli diet-induced alcoholic and methionine choline deficient diet-induced nonalcoholic steatohepatitis models in mice. Alcohol Clin Exp Res 2009;33(10):1704-10.

Yeligar S, Tsukamoto H, Kalra VK. Ethanol-induced expression of ET-1 and ET-BR in liver sinusoidal endothelial cells and human endothelial cells involves hypoxia-inducible factor-1alpha and microrNA-199. J Immunol 2009;183(8):5232-43.

Kang T, Lu W, Xu W, Anderson L, Bacanamwo M, Thompson W, et al. MicroRNA-27 (miR-27) targets prohibitin and impairs adipocyte differentiation and mitochondrial function in human adipose-derived stem cells. J Biol Chem 2013;288(48):34394-402. doi: 10.1074/jbc.M113.514372.

Feng J, Wang J, Chen M, Chen G, Wu Z, Ying L, et al. MiR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. Oncol Rep 2015;33(2):713-20.

Bukong TN, Hou W, Kodys K, Szabo G. Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 2013;57(1):70-80.

Hou W, Bukong TN, Kodys K, Szabo G. Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 2013;37(4):599-608.

Habior A. Nonalcoholic fatty liver disease and obesity. Post Nauk Med 2013;5b:31-7.

Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I, et al. Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest 2010;90(10): 1437-46.

Cheung O, Puri P, Eicken C, Contos MJ, Mirshahi F, Maher JW, et al. Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 2008;48(6):1810-20. doi: 10.1002/hep.22569.

Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011;91(2):283-93.

Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69(15):6275-81.

Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 2006;103(33):12481- 6. doi: 10.1073/pnas.0605298103.

Tang B, Xiao B, Liu Z, Li N, Zhu ED, Li BS, et al. Identification of MyD88 as a novel target of miR-155, involved in negative regulation of Helicobacter pylori-induced inflammation. FEBS Lett 2010;584(8):1481-6. doi: 10.1016/j.febslet.2010.02.063.

Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines theepithelial phenotype of cancer cells by targeting the E-cadherin repressors

Ahn J, Lee H, Chung CH, Ha T. High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. Biochem Biophys Res Commun 2011;414(4):664-9

Zhang Y, Cheng X, Lu Z, Wang J, Chen H, Fan W, et al. Upregulation of miR-15b in NAFLD models and in the serum of patients with fatty liver diseaseDiabetes Res Clin Pract 2013;99(3):327-34..

Zhang ZC, Liu Y, Xiao LL, Li SF, Jiang JH, Zhao Y, et al. Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol 2015;63(6):1466-75.

Fisher K, Vuppalanchi R, Saxena R. Drug-induced liver injury. Arch Pathol Lab Med 2015;139(7):876-87.

Fukushima T, Hamada Y, Yamada H, Horii I. Changes of micro-RNA expression in rat liver treated by acetaminophen or carbon tetrachloride – regulating role of micro-RNA for RNA expression. J Toxicol Sci 2007;32(4):401-9.

Pogribny IP, Tryndyak VP, Boyko A, Rodriguez-Juarez R, Beland FA, Kovalchuk O. Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 2007;619(1-2):30-7.

Endo S, Yano A, Fukami T, Nakajima M, Yokoi T. Involvement of miRNAs in the early phase of halothane-induced liver injury. Toxicology 2014;319:75-84.

Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106(11):4402-7.

Yoshioka W, Higashiyama W, Tohyama C. Involvement of microRNAs in dioxin-induced liver damage in the mouse. Toxicol Sci 2011;122(2):457-65.

Strillacci A, Griffoni C, Sansone P, Paterini P, Piazzi G, Lazzarini G, et al. MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp Cell Res 2009;315(8):1439-47.

Moffat ID, Boutros PC, Celius T, Lindén J, Pohjanvirta R, Okey AB. MicroRNAs in adult rodent liver are refractory to dioxin treatment. Toxicol Sci 2007;99(2):470-87.

Yang W, Lian J, Feng Y, Srinivas S, Guo Z, Zhong H, et al. Genome-wide miRNA-profiling of aflatoxin B1-induced hepatic injury using deep sequencing. Toxicol Lett 2014;226(2):140-9.

Malik AI, Williams A, Lemieux CL, White PA, Yauk CL. Hepatic mRNA, microRNA, and miR-34a-target responses in mice after 28 days exposure to doses of benzo(a)pyrene that elicit DNA damage and mutation. Environ Mol Mutagen 2012;53(1):10-21.

Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32(3-4):246-53.

Banales JM, Sáez E, Uriz M, Sarvide S, Urribarri AD, Splinter P, et al. Upregulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology 2012;56(2):687-97.

Tan Y, Pan T, Ye Y, Ge G, Chen L, Wen D, et al. Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One 2014;9(10):e111424.

Migita K, Komori A, Kozuru H, Jiuchi Y, Nakamura M, Yasunami M, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One 2015;(11):e0136908.

Voigtländer T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS One 2015;10(10):e0139305.

Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marzioni M, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol 2016;185(1):61-71. doi: 10.1111/cei.12776.

Li J, Fu H, Xu C, Tie Y, Xing R, Zhu J, et al. MiR-183 inhibits TGF-beta1- induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 2010;10:354.

Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu W, et al. MicroRNA-21 acts as an oncomir through multiple targets in human hepatocellular carcinoma. J Hepatol 2010;53(1):98-107.

Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, et al. MiR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009;275(1):44-53.

Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012;33(6):1134-41.

Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, et al. Hepatitis C virusinduced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012;56(5)1631-40. doi: 10.1002/hep.25849.

Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010;16(3):867-75.

Ding X, Ding J, Ning J, Yi F, Chen J, Zhao D, et al. Circulating microRNA-122 as a potential biomarker for liver injury. Mol Med Rep 2012;5(6):1428-32. doi: 10.3892/mmr.2012.838.

Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102(39):13944-9.

Wu CS, Yen CJ, Chou RH, Chen JN, Huang WC, Wu CY, et al. Downregulation of microRNA-15b by hepatitis B virus X enhances hepatocellular carcinoma proliferation via fucosyltransferase 2-induced Globo H expression. Int J Cancer 2014;134(7):1638-47.

Yan X, Liang H, Deng T, Zhu K, Zhang S, Wang N, et al. The identification of novel targets of miR-16 and characterization of their biological functions in cancer cells. Mol Cancer 2013;12:92.

Asangani I, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27(15):2128-36.

Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007;282(19):14328-36.

Connolly EC, van Doorslaer K, Rogler LE, Rogler CE. Overexpression of miR-21 promotes an in vitro metastatic phenotype by targeting the tumor suppressor RHOB. Mol Cancer Res 2010;8(5):691-700.

Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O’Day E, et al. MiR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3’UTR microRNA recognition elements. Mol Cell 2009;35(5):610-25.

Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, et al. MiR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One 2010;5(2):e9429.

Wang T, Xu Z. MiR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem Biophys Res Commun 2010;402(2):186-9.

Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66(24):11590-3.

Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b that represses Mcl-1, collagens, and matrix-metalloproteinase-2 in prostate cancer cells. Genes Cancer 2010;1(4):381-7.

Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008;582(10):1564-8.

Ding J, Li M, Wan X, Jin X, Chen S, Yu C, et al. Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease. Sci Rep 2015;5:13729. doi: 10.1038/srep13729.

Niu H, Wang K, Zhang A, Yang S, Song Z, Wang W, et al. MiR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. Oncol Rep 2012;28(5):1771-7.

Chen ZL, Zhao XH, Wang JW, Li BZ, Wang Z, Sun J, et al. MicroRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem 2011;286(12):10725-34.

Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo YY, et al. Targeting DNAPKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 2010;5(7):e11397.

Wei X, Tang C, Lu X, Liu R, Zhou M, He D, et al. MiR-101 targets DUSP1 to regulate the TGF-f secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma. Oncotarget 2015;6(21):18389-405.

Lin CJ, Gong HY, Tseng HC, Wang WL, Wu JL. miR-122 targets an antiapoptotic gene, Bcl-w, in human hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2008;375(3):315-20. doi: 10.1016/j.bbrc. 2008.07.

Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007;67(13):6092-9.

. Xu H, He JH, Xiao ZD, Zhang QQ, Chen YQ, Zhou H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology 2010;52(4):1431-42.

. Li J, Ghazwani M, Zhang Y, Lu J, Li J, Fan J, et al. MiR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J Hepatol 2013;58(3):522-8.

Wang HQ, Yu XD, Liu ZH, Cheng X, Samartzis D, Jia LT, et al. Deregulated miR-155 promotes Fas-mediated apoptosis in human intervertebral disc degeneration by targeting FADD and caspase-3. J Pathol 2011;225(2):232-42. doi: 10.1002/path.2931.

Zhu D, Xie H, Li H, Cai P, Zhu H, Xu C, et al. Nidogen-1 is a common target of microRNAs MiR-192/215 in the pathogenesis of Hirschsprung’s disease. J Neurochem 2015;134(1):39-46. doi: 10.1111/jnc.13118.

Lian J, Jing Y, Dong Q, Huan L, Chen D, Bao C, et al. MiR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma. Oncotarget 2016;7(3): 2672-83.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010;18(4):367-81.

Zhang Y, Fan KJ, Sun Q, Chen AZ, Shen WL, Zhao ZH, et al. Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-f signalling pathway. Nucleic Acids Res 2012;40(18):9286-97.

Shatseva T, Lee DY, Deng Z, Yang BB. MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J Cell Sci 2011;124:2826-36.

Han Y, Kuang Y, Xue X, Guo X, Li P, Wang X, et al. NLK, a novel target of miR- 199a-3p, functions as a tumor suppressor in colorectal cancer. Biomed Pharmacother 2014;68(5):497-505.

Schickel R, Park SM, Murmann AE, Peter ME. MiR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010;38(6):908-15.

Nie J, Liu L, Zheng W, Chen L, Wu X, Xu Y, et al. microRNA-365, downregulated in colon cancer, inhibits cell cycle progression and promotes apoptosis of colon cancer cells by probably targeting Cyclin D1 and Bcl-2. Carcinogenesis 2012:33(1):220-5. doi: 10.1093/carcin/bgr245.

Guo SL, Ye H, Teng Y, Wang YL, Yang G, Li XB, et al. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat Commun 2013;4:2544. doi: 10.1038/ncomms3544.

Zhang J, Bian Z, Zhou J, Song M, Liu Z, Feng Y, et al. MicroRNA-638 inhibits cell proliferation by targeting phospholipase D1 in human gastric carcinoma. Protein Cell 2015;6(9):680-8. doi: 10.1007/s13238-015-0187-8.

Tay Y, Tan SM, Karreth FA, Lieberman J, Pandolfi PP. Characterization of dual PTEN and p53-targeting microRNAs identifies microRNA-638/Dnm2 as a two-hit oncogenic locus. Cell Rep 2014;8(3):714-22. doi: 10.1016/j. celrep.2014.06.064.

Xie KL, Zhang YG, Liu J, Zeng Y, Wu H. MicroRNAs associated with HBV infection and HBV-related HCC. Theranostics 2014;4(12):1176-92. doi: 10.7150/thno.8715.

Enache LS, Enache EL, Ramière C, Diaz O, Bancu L, Sin A, et al. Circulating RNA molecules as biomarkers in liver disease. Int J Mol Sci 2014;15(10):17644-66. doi: 10.3390/ijms151017644.

Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 2010;398(1):57-67.

Jiang M, Broering R, Trippler M, Wu J, Zhang E, Zhang X, et al. MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver. J Viral Hepat 2014;21(2):99-110.

Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol 2013;5(9):479-86. doi: 10.4254/wjh.v5.i9.479.

Bala S, Szabo G. MicroRNA signature in alcoholic liver disease. Int J Hepatol 2012;2012:498232. doi: 10.1155/2012/498232.

McDaniel K, Herrera L, Zhou T, Francis H, Han Y, Levine P, et al. The functional role of microRNAs in alcoholic liver injury. J Cell Mol Med 2014;18(2):197-207.

Chen YP, Jin X, Xiang Z, Chen SH, Li YM. Circulating MicroRNAs as potential biomarkers for alcoholic steatohepatitis. Liver Int 2013;33(8):1257-65.

Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012;56(5):1946-57.

Szabo G, Csak T. Role of microRNAs in NAFLD/NASH. Dig Dis Sci 2016;61(5):1314-24. doi: 10.1007/s10620-015-4002-4.

Sobolewski C, Calo N, Portius D, Foti M. MicroRNAs in fatty liver disease. Semin Liver Dis 2015;35(1):12-25.

Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 2015;7(2):226-34.

Tryndyak VP, Latendresse JR, Montgomery B, Ross SA, Beland FA, Rusyn I, et al. Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet. Toxicol Appl Pharmacol 2012;262(1):52-9.

Wang Y, Chen T, Tong W. miRNAs and their application in drug-induced liver injury. Biomark Med 2014;8(2):161-72. doi: 10.2217/bmm.13.147.

Yan S, Wang J, Zhang W, Dai J. Circulating microRNA profiles altered in mice after 28 d exposure to perfluorooctanoic acid. Toxicol Lett 2014;224(1):24-31.

Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009;55(11):1977-83. doi: 10.1373/ clinchem.2009.131797.

Wang J, Zhang Y, Zhang W, Jin Y, Dai J. Association of perfluorooctanoic acid with HDL cholesterol and circulating miR-26b and miR-199-3p in workers of a fluorochemical plant and nearby residents. Environ Sci Technol 2012;46(17):9274-81.

Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated microRNAs in progression of hepatocellular carcinoma: A systematic review. Hepatol Res 2016;46(5):391-406. doi: 10.1111/hepr.12606.

Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009;137(6):1005-17.

Wang C, Ren R, Hu H, Tan C, Han M, Wang X, et al. MiR-182 is up-regulated and targeting Cebpa in hepatocellular carcinoma. Chin J Cancer Res 2014;26(1):17-29. doi: 10.3978/j.issn.1000-9604.2014.01.01.

Chang-Hao Tsao S, Behren A, Cebon J, Christophi C. The role of circulating microRNA in hepatocellular carcinoma. Front Biosci (Landmark Ed) 2015;20:78-104.

Wang X, Zhang J, Zhou L, Lu P, Zheng ZG, Sun W, et al. Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): clinical analyses of patients and an HCC rat model. Int J Clin Exp Pathol 2015;8(2):1466-78.




DOI: https://doi.org/10.21164/pomjlifesci.173

Copyright (c) 2016 Sylwia Szeląg, Mateusz Kurzawski

License URL: https://creativecommons.org/licenses/by-nc-nd/3.0/pl/